Recent advances with immunotherapy agents for the treatment of cancer has provided remarkable, and in some cases, curative results. Our laboratory has identified CD47 as 
Background
Tumors are able to evade immune recognition and removal through multiple processes including creating an immunosuppressive environment, or direct tumor:immune cell interactions (1) (2) (3) (4) . One mechanism to avoid removal by innate immune cells (macrophages and dendritic cells) is to upregulate "don't eat me" signals preventing phagocytosis (5) . In addition to preventing programed cell removal (PrCR) by reducing total phagocytosis, antigen presentation from innate to adaptive immune cells is limited thereby restricting the cross-presentation to the adaptive immune cells (1, 4) . As a result, immunotherapies that increase tumor cell recognition by innate immune cells should also act as stimulation to the adaptive immune response in vivo.
CD47-a "don't eat me" signal on cells
CD47, a transmembrane protein found ubiquitously expressed on normal cells to mark "self" has increased expression in circulating hematopoietic stem cells (HSCs), red blood cells (RBCs), and a high proportion of malignant cells (4, 5) . Although CD47 has multiple functions in normal cell physiology, in cancer it acts primarily as a dominant "don't eat me" signal ( Fig. 1) (4, 5) . On tumor cells pro-phagocytic signals may be present, but if the tumor cells are expressing CD47 it can bind with signal regulatory protein-α (SIRP-α) on phagocytic immune cells preventing engulfment ( Fig. 1) (4, (6) (7) (8) .
CD47:SIRP-α engagement results in activation of SIRP-α by which phosphorylation of immunoreceptor tyrosine-based inhibition (ITIM) motifs leading to the recruitment of Src homology phosphatase-1 (SHP-1) and SHP-2 phosphatases preventing myosin-IIA accumulation at the phagocytic synapse preventing phagocytosis ( Fig. 1) (9) . This inhibitory mechanism of CD47 expression is seen in a broad range of malignancies and is therefore an attractive therapeutic target for all tumors expressing CD47 (5, 6, (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) .
In pre-clinical models, disruption of CD47:SIRP-α axis results in enhanced phagocytosis, tumor reduction, and recently has been demonstrated as a means to cross present tumor antigens to T cells ( Fig. 1) (11, 15) .
To date, several strategies to block CD47:SIRP-α interaction have been developed including antibodies or antibody fragments against CD47 or SIRP-α (6, 19, 23) , small peptides that bind CD47 or SIRP-α (12, 16), or systemic knockdown of CD47 expression (6, 15, 21) . One advantage of antibodies that target CD47 is the increase in antibody dependent cellular phagocytosis (ADCP) which occurs when innate immune cells (macrophages and dendritic cells) Fcγ receptors (FcγR) bind to the Fc portion of the anti-CD47 antibody (6, 24, 25) . To further increase antibody dependent cellular phagocytosis anti-CD47 combination with additional tumor targeting antibodies has been tested pre-clinically and shown strong synergy in reducing total tumor burden in mice (6, 12, 16, 18) . The majority of these studies have been performed in NSG mice, which contain innate immune cells, but lack T, B and natural killer (NK) cells. NK cells are the dominant cells responsible for antibody dependent cell-mediated cytotoxicity (ADCC), as a result the effects of NK cells after anti-CD47 treatment are not well studied (6, 26) . Consequently, only a limited number of studies have investigated how CD47:SIRP-α blockade primes the adaptive immune response in immunocompetent systems.
Activating adaptive anti-tumor immunity in vivo
Activation of the adaptive immune system, T and B cells, is antigen-specific and allows for a targeted immune response. T cells specificity comes from their T cell receptor Fig. 1) (27) . Naïve T cells need an initial activation by APCs that have phagocytosed tumor cells and present these tumor neo-antigens (1, 3, 27) . TCR/MHC recognition as well as engagement of additional co-stimulatory molecules occurs between the T cell/APC causing rapid expansion, cytokine production, and development of a memory T cell subset ( Fig. 1) (1, 3, 27) 
Pre-clinical evaluation for activating the adaptive immune response following

CD47 blockade
In vitro, we have demonstrated that macrophages and dendritic cells increased their phagocytosis of tumor cells expressing the Ovalbumin antigen (Ova) when cells were treated with anti-CD47 (11) . In this study and others by our lab, macrophages were the dominant phagocytic cell after anti-CD47 treatment (4, 11, 17) . After phagocytosis, these macrophages secreted pro-inflammatory cytokines, and upregulated the costimulatory molecule CD86. These macrophages were then co-cultured with Ova 
affinity SIRP-α mimics including a fusion protein "SIRPαFc" that combines a portion of SIRP-α fused to the Fc region of an antibody to retain ADCP.
Potential adverse events or resistance mechanisms in CD47 blockade
In clinical applications, anti-CD47 is not predicted to have adverse drug interactions or side effects. Anticipated off-target effects of CD47:SIRP-α blockade include potential allergic reactions to humanized antibodies, or removal of non-malignant CD47 expressing cells (4) . In particular, CD47 expression on red blood cells is a mechanism that prevents programed cell removal (32) . Initial dosing of anti-CD47 is therefore expected to cause a significant reduction in total red blood cell count. To lessen this effect, a priming dose of anti-CD47 can be given to remove "aged" red blood cells and to stimulate erythropoiesis (J. Liu et al.; manuscript in preparation). Newly developed red blood cells should not be significantly affected during the remaining anti-CD47 therapy. If red blood cell counts remain low after priming and during therapy, erythropoietin or transfusions can also be given to alleviate this.
An additional concern of a new drug is potential resistance including loss of expression, amplification, mutations, or alternative non-CD47 related tumor cell adaptations. To date no common mechanisms have been described pre-clinically. Loss of CD47 by tumor cells is not expected, and if this occurs it will mimic the blocking effect of anti-CD47. Amplification will not cause total resistance but may be one mechanism to dampen efficacy if therapeutic antibody dosing is not at an antigen saturating level.
Mutations in CD47 may occur, but these need to prevent antibody binding while retaining the CD47:SIRP-α interaction. Alternatively, the upregulation of additional "don't eat me" or "immune tolerance" signals can cause resistance (31) . These changes may be induced after anti-CD47 therapy, or might be present initially and will be selected for during therapy. Identifying the resistance mechanism to anti-CD47 clinically can provide information on additional future drug targets, or combination therapies to reduce the identified resistance.
Identifying synergistic combination therapies with CD47 blockade
Based on preclinical studies, anti-CD47 (and SIRPαFc) is expected to have efficacy as a monotherapy, with the most promising preclinical data in acute myelogenous leukemia 
